Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study
2011-004977-10Phase 3Withdrawn
- Sponsor
- University Hospital Basel
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydralazine in Acute Heart Failure (AHF) and heart failure (HF) (2 arms), sponsored by University Hospital Basel. Primary endpoint: Composite of death or heart failure re-hospitalization at 180 days. Planned start May 2012; status: withdrawn.
02
Drugs
hydralazine
03
Conditions
Acute Heart Failure (AHF)heart failure (HF)
Beyond the preview
Go deeper on 2011-004977-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004977-10.